CDIO Quote, Financials, Valuation and Earnings

CEL-SCI Corp. has a net margin of -59120.69% compared to Cardio Diagnostics Holdings, Inc.'s net margin of --. Cardio Diagnostics Holdings, Inc.'s return on equity of -77.09% beat CEL-SCI Corp.'s return on equity of -266.61%.

Cardio Diagnostics Holdings, Inc. has a consensus price target of $2.00, signalling upside risk potential of 1757.59%. On the other hand CEL-SCI Corp. has an analysts' consensus of $42.50 which suggests that it could grow by 765.58%. Given that Cardio Diagnostics Holdings, Inc. has higher upside potential than CEL-SCI Corp., analysts believe Cardio Diagnostics Holdings, Inc. is more attractive than CEL-SCI Corp..

Cardio Diagnostics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison CEL-SCI Corp. has a beta of 0.487, suggesting its less volatile than the S&P 500 by 51.259%.

Cardio Diagnostics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. CEL-SCI Corp. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardio Diagnostics Holdings, Inc. pays -- of its earnings as a dividend. CEL-SCI Corp. pays out -- of its earnings as a dividend.

Cardio Diagnostics Holdings, Inc. quarterly revenues are $2.9K, which are larger than CEL-SCI Corp. quarterly revenues of --. Cardio Diagnostics Holdings, Inc.'s net income of -$1.7M is higher than CEL-SCI Corp.'s net income of -$5.7M. Notably, Cardio Diagnostics Holdings, Inc.'s price-to-earnings ratio is -- while CEL-SCI Corp.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardio Diagnostics Holdings, Inc. is 343.17x versus -- for CEL-SCI Corp.. Usually stocks with elevated PS ratios are considered overvalued.

IGC Pharma, Inc. has a net margin of -59120.69% compared to Cardio Diagnostics Holdings, Inc.'s net margin of -953.4%. Cardio Diagnostics Holdings, Inc.'s return on equity of -77.09% beat IGC Pharma, Inc.'s return on equity of -94.42%.

Cardio Diagnostics Holdings, Inc. has a consensus price target of $2.00, signalling upside risk potential of 1757.59%. On the other hand IGC Pharma, Inc. has an analysts' consensus of $3.88 which suggests that it could grow by 1191.67%. Given that Cardio Diagnostics Holdings, Inc. has higher upside potential than IGC Pharma, Inc., analysts believe Cardio Diagnostics Holdings, Inc. is more attractive than IGC Pharma, Inc..

Cardio Diagnostics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison IGC Pharma, Inc. has a beta of 0.242, suggesting its less volatile than the S&P 500 by 75.839%.

Cardio Diagnostics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. IGC Pharma, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardio Diagnostics Holdings, Inc. pays -- of its earnings as a dividend. IGC Pharma, Inc. pays out -- of its earnings as a dividend.

Cardio Diagnostics Holdings, Inc. quarterly revenues are $2.9K, which are smaller than IGC Pharma, Inc. quarterly revenues of $191K. Cardio Diagnostics Holdings, Inc.'s net income of -$1.7M is higher than IGC Pharma, Inc.'s net income of -$1.8M. Notably, Cardio Diagnostics Holdings, Inc.'s price-to-earnings ratio is -- while IGC Pharma, Inc.'s PE ratio is --. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardio Diagnostics Holdings, Inc. is 343.17x versus 22.51x for IGC Pharma, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

NovaBay Pharmaceuticals, Inc. has a net margin of -59120.69% compared to Cardio Diagnostics Holdings, Inc.'s net margin of -255.85%. Cardio Diagnostics Holdings, Inc.'s return on equity of -77.09% beat NovaBay Pharmaceuticals, Inc.'s return on equity of -306.03%.

Cardio Diagnostics Holdings, Inc. has a consensus price target of $2.00, signalling upside risk potential of 1757.59%. On the other hand NovaBay Pharmaceuticals, Inc. has an analysts' consensus of $0.85 which suggests that it could fall by -83.96%. Given that Cardio Diagnostics Holdings, Inc. has higher upside potential than NovaBay Pharmaceuticals, Inc., analysts believe Cardio Diagnostics Holdings, Inc. is more attractive than NovaBay Pharmaceuticals, Inc..

Cardio Diagnostics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison NovaBay Pharmaceuticals, Inc. has a beta of 0.569, suggesting its less volatile than the S&P 500 by 43.103%.

Cardio Diagnostics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. NovaBay Pharmaceuticals, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.80 per share. Cardio Diagnostics Holdings, Inc. pays -- of its earnings as a dividend. NovaBay Pharmaceuticals, Inc. pays out -- of its earnings as a dividend.

Cardio Diagnostics Holdings, Inc. quarterly revenues are $2.9K, which are smaller than NovaBay Pharmaceuticals, Inc. quarterly revenues of $521K. Cardio Diagnostics Holdings, Inc.'s net income of -$1.7M is lower than NovaBay Pharmaceuticals, Inc.'s net income of -$1.3M. Notably, Cardio Diagnostics Holdings, Inc.'s price-to-earnings ratio is -- while NovaBay Pharmaceuticals, Inc.'s PE ratio is 8.90x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardio Diagnostics Holdings, Inc. is 343.17x versus 10.30x for NovaBay Pharmaceuticals, Inc.. Usually stocks with elevated PS ratios are considered overvalued.

Protalix Biotherapeutics, Inc. has a net margin of -59120.69% compared to Cardio Diagnostics Holdings, Inc.'s net margin of 13.19%. Cardio Diagnostics Holdings, Inc.'s return on equity of -77.09% beat Protalix Biotherapeutics, Inc.'s return on equity of 12.06%.

Cardio Diagnostics Holdings, Inc. has a consensus price target of $2.00, signalling upside risk potential of 1757.59%. On the other hand Protalix Biotherapeutics, Inc. has an analysts' consensus of $11.00 which suggests that it could grow by 535.84%. Given that Cardio Diagnostics Holdings, Inc. has higher upside potential than Protalix Biotherapeutics, Inc., analysts believe Cardio Diagnostics Holdings, Inc. is more attractive than Protalix Biotherapeutics, Inc..

Cardio Diagnostics Holdings, Inc. has a beta of 0.000, which suggesting that the stock is 100% less volatile than S&P 500. In comparison Protalix Biotherapeutics, Inc. has a beta of -0.248, suggesting its less volatile than the S&P 500 by 124.798%.

Cardio Diagnostics Holdings, Inc. has a quarterly dividend of $0.00 per share corresponding to a yield of 0%. Protalix Biotherapeutics, Inc. offers a yield of 0% to investors and pays a quarterly dividend of $0.00 per share. Cardio Diagnostics Holdings, Inc. pays -- of its earnings as a dividend. Protalix Biotherapeutics, Inc. pays out -- of its earnings as a dividend.

Cardio Diagnostics Holdings, Inc. quarterly revenues are $2.9K, which are smaller than Protalix Biotherapeutics, Inc. quarterly revenues of $17.9M. Cardio Diagnostics Holdings, Inc.'s net income of -$1.7M is lower than Protalix Biotherapeutics, Inc.'s net income of $2.4M. Notably, Cardio Diagnostics Holdings, Inc.'s price-to-earnings ratio is -- while Protalix Biotherapeutics, Inc.'s PE ratio is 24.89x. Generally a lower price-to-earnings ratio signals a stock is trading at a lower multiple of earnings and is a better value. Another key metric is the price-to-sales ratio, which for Cardio Diagnostics Holdings, Inc. is 343.17x versus 2.20x for Protalix Biotherapeutics, Inc.. Usually stocks with elevated PS ratios are considered overvalued.